Literature DB >> 8188761

Uneven distribution of protein kinase C-alpha and -beta isozymes in human sarcomas and carcinomas.

A Cuadrado1, W Issing, T P Fleming, C J Molloy.   

Abstract

Protein kinase C (PKC) represents a family of structurally related Ser/Tre kinases which are involved in mitogenic signalling and may contribute to human neoplasia. To address this issue, the messenger RNA and protein levels of PKC isoenzymes alpha and beta were analyzed in several human sarcoma- and carcinoma-derived cell lines. Carcinomas contained low or undetectable levels of either PKC-alpha or PKC-beta. Sarcomas exhibited similar or increased PKC expression compared to human diploid fibroblasts. Moreover, sarcoma cell lines expressing one PKC isoform did not contain detectable levels of the other. When PKC was depleted from the tumor cells, we observed that the PKC overexpressing sarcomas had reduced their malignant properties as determined by their ability to grow in semisolid medium. In addition, epidermal growth factor-stimulated and erbB2-transformed fibroblasts exhibited enhanced cell growth in the absence of PKC. We propose a model for the effect of PKC as a negative regulator of proliferation in epithelial cells and a growth promoter in fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188761     DOI: 10.1002/jcp.1041590307

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  3 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

2.  Protein kinase C isotype expression and regulation of lymphoid cell motility.

Authors:  K M Thorp; H Verschueren; P De Baetselier; C Southern; N Matthews
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

3.  A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.

Authors:  M Knowling; M Blackstein; R Tozer; V Bramwell; J Dancey; N Dore; S Matthews; E Eisenhauer
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.